Back to News

Ori Biotech: Europe’s rising 100 B2B companies.

Thank you Sifted for naming Ori Biotech in their ultimate shortlist of Europe’s future 100 unicorns! 

Recognized as having the potential to “one day join the ranks of $1bn-plus start-ups”, the report lists the most promising VC-backed B2B companies – from health to fintech – shortlisted from a list of over 480.

We are inspired to be named among a group of wonderful companies all making waves in their respective industries. Healthtech companies highlighted in the shortlist include LifebitProximie and padoa.

This year has been very exciting for Ori, kicking off with our $100M Series B raise. Recognition from the wider industry helps spur us on in our mission to enable widespread patient access to cell and gene therapies.

View the list of Europe’s rising 100

Share this page